Correlation between deleted in liver cancer-1 expression and clinicopathological parameters of human pituitary adenoma

( views:121, downloads:0 )
Author:
ZHANG Feng-lin(Department of Neurosurgery, No.411 Hospital of PLA, Shanghai 200081, China)
DING Xue-hua()
YING-Qi(Department of Neurosurgery, No.411 Hospital of PLA, Shanghai 200081, China)
WANG Mao-mao(Department of Neurosurgery, No.411 Hospital of PLA, Shanghai 200081, China)
TIAN Xiao-jin(Department of Neurosurgery, No.411 Hospital of PLA, Shanghai 200081, China)
Journal Title:
Chinese Journal of Neuromedicine
Issue:
Volume 11, Issue 01, 2012
DOI:
10.3760/cma.j.issn.1671-8925.2012.01.004
Key Word:
Deleted in liver cancer-l;Ki-67;Pituitary adenoma;Invasiveness

Abstract: Objective To determine the expression level of deleted in liver cancer-1 (DLC-1)gene in human pituitary tumors, and assess the correlation between DLC-1 expression and clinicopathological parameters in these tumors. Methods DLC-1 and Ki-67 protein expressions were analyzed by immunohistochemistry and DLC-1 mRNA expression by quantitative RT-PCR in 84 pituitary adcnomas and 6 normal human adenohypophyses. Results Immunohistochemical results suggested that DLC-1 expression decreased and Ki-67 expression increased in the pituitary adenomas; Pearson correlation analysis showed that they were negatively correlated (r=-0.764,P=0.001).RT-PCR indicated that DLC-1 mRNA expression decreased in the pituitary adenomas; significantly decreased DLC-1 expression in invasive pituitary adenomas was noted as compared with that in non-invasive ones (P<0.05). Conclusion Down-regulation of DLC-1 expression may contribute to the tumorigenesis of pituitary adenomas and DLC-1 can be the new target of molecular therapy.

  • [1]Durkin ME,Yuan BZ,Zhou X,et al.DLC-1:a Rho GTPase-activating protein and tumour suppressor[J].J Cell Mol Med,2007,11(5):1185-1207.
  • [2]Shimizu M,Saitoh Y,Itoh H.Immunohistochemical staining of Ha-ras oncogene product in normal,benign,and malignant human pancreatic tissues[J].Hum Pathol,1990,21(6):607-612.
  • [3]Livak K J,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method[J].Methods,2001,25(4):402-408.
  • [4]周崧,江基尧.垂体腺瘤的分子病因学研究进展[J].中华神经医学杂志,2007,6(8):856-858.
  • [5]Asa SL,Ezzat S.The pathogenesis of pituitary tumors[J].Annu Rev Pathol,2009,4(1):97-126.
  • [6]Yuan BZ,Miller M J,Keck CL,et al.Cloning,characterization,and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP[J].Cancer Res,1998,58(10):2196-2199.
  • [7]Kim TY,Vigil D,Der CJ,et al.Role of DLC-1,a tumor suppressor protein with RhoGAP activity,in regulation of the cytoskeleton and cell motility[J].Cancer Metastasis Rev,2009,28(1-2):77-83.
  • [8]Ullmannova V,Popescu NC.Expression profile of the tumor suppressor genes dlc-1 and dlc-2 in solid tumors[J].Int J Oncol,2006,29(5):1127-1132.
  • [9]Hankins GR,Sasaki T,Lieu AS,et al.Identification of the deleted in liver cancer 1 gene,dlcl,as a candidate maningioma tumor suppressor[J].Neurosurgery,2008,63(4):771-780.
  • [10]马林,张建宁,王新军,等.Nucleostemin和Ki-67在垂体腺瘤组织中的表达及其临床意义[J].中华神经医学杂志,2008,7(4):343-346.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn